AMG 714

Drug Profile

AMG 714

Alternative Names: HuMab-IL15; HuMax anti-IL15; HuMax-IL15

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genmab
  • Developer Amgen; Celimmune
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease
  • Discontinued Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2016 Phase-II clinical trials in Coeliac disease in Finland (IV) (EudraCT-2015-004063-36)
  • 31 Mar 2016 Phase-II clinical trials in Coeliac disease in Netherlands (IV) (EudraCT-2015-004063-36)
  • 31 Mar 2016 Celimmune initiates a phase II trial for Coeliac disease (gluten-free diet non-responsive)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top